DelveInsight’s ‘Ankylosing Spondylitis (AS)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States.
The Ankylosing Spondylitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted AS market size from 2018 to 2030. The Report also covers current AS treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Ankylosing Spondylitis (AS) Overview
Ankylosing Spondylitis (AS) also called as Bechterew's disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women.
General onset of AS commonly occurs in younger people, between the ages of 17 and 45. However, it can also affect children and those who are much older (Spondylitis association of america).AS is a type of spondyloarthropathy (SpA)—Spondyloarthropathies are a family of related inflammatory rheumatic disorders which also include reactive arthritis (RA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease—and is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. It has also been found that such patients quite often have a family history of either AS or another spondyloarthropathy.
Continued in the report…..
Ankylosing Spondylitis (AS) Diagnosis
The most commonly used criteria for the classification of AS were developed in 1966 and modified in 1984. They are:
1. Low back pain of at least three months duration with inflammatory characteristics (improved by exercise, not relieved by rest)
2. Limitation of lumbar spine motion in sagittal and frontal planes
3. Decreased chest expansion (relative to normal values for age and sex)
4. Bilateral sacroiliitis grade 2 or higher
5. Unilateral sacroiliitis grade 3 or higher.
Definite AS is said to be present when the fourth or fifth criterion presents with any clinical criteria. However, radiological sacroiliitis may not develop for many years, and the development of new criteria (including magnetic resonance imaging) has been proposed to allow confirmation of the diagnosis in patients with early disease.
Continued in the report…..
Ankylosing Spondylitis (AS) Treatment
Treatment of Ankylosing spondylitis will depend on the symptoms, age, and general health. It will also depend on how severe the condition is. The treatment goal is to reduce pain and stiffness, prevent deformities, and maintain as normal lifestyle as possible. Treatment may include: Nonsteroidal anti-inflammatory medications to reduce pain and inflammation, tumor-necrosis-factor blockers (biologic medications) to reduce inflammation and swelling, disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine to decrease inflammation and control AS, short-term use of corticosteroids to reduce inflammation, short-term use of muscle relaxants and pain relievers to relieve severe pain and muscle spasms, surgery to replace a joint, place rods in the spine, or remove parts of the thickened and hardened bone. Moreover, maintaining proper posture and regular exercise, including exercises that strengthen back muscles, is vital (Johns Hopkins Medicine, n.d.).
Continued in the report…..
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Ankylosing Spondylitis, Diagnosed Prevalence of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis, Age-specific Diagnosed Prevalence of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis scenario in the the United States from 2018 to 2030.
Key Findings
“The diagnosis of Ankylosing Spondylitis can be tough to spot as so many people have back pain—its main symptom. Additionally, there are no specific lab tests to identify ankylosing spondylitis. All these factors play a major role in the low diagnosis of AS. Due to the increase in advancement, it is estimated that in the coming years, the diagnosis rate may increase.”
The epidemiology segment also provides the AS epidemiology data and findings across the United States.
Ankylosing Spondylitis (AS) Emerging Drugs
Tofacitinib: Pfizer
Tofacitinib (CP-690,550) is a Janus kinase inhibitor. In the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.The drug is approved in the US for four indications: adults with moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, adults with active psoriatic arthritis (PsA) after disease-modifying antirheumatic drug (DMARD) failure, adults with moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Bimekizumab: UCB Biopharma
Bimekizumab (UCB4940) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes IL-17A and IL-17F. These are the two key pro-inflammatory cytokines that share similar biological function and structural homology. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. This therapeutic candidate is in the phase III stage of development to treat patients with Ankylosing Spondylitis (AS). The company is using the subcutaneous route of administration for AS.
Products detail in the report…
List to be continued in the report…
Ankylosing spondylitis (AS) is an inflammatory disease that, over time, can cause some of the small bones in the spine (vertebrae) to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture. If ribs are affected, it can be difficult to breathe deeply. There is no cure for AS, but treatments can lessen your symptoms and possibly slow progression of the disease. Recent studies show that the newer biologic medications can potentially slow disease progression in some people. Different people respond to different medications with varying levels of effectiveness. Thus, it may take time to find the most effective course of treatment.
A common treatment regimen for the various forms of spondyloarthritis (AS, psoriatic arthritis, enteropathic arthritis, reactive arthritis, juvenile spondyloarthritis, and undifferentiated spondyloarthritis) involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. In severe cases, posture correcting surgery may also be an option.
Depending on the type of spondyloarthritis, there may be some variation in treatment. For example, in psoriatic arthritis, both the skin component and joint component must be treated. In enteropathic arthritis (spondylitis/arthritis associated with inflammatory bowel disease), medications may need to be adjusted so the gastrointestinal component of the disease is also treated and not exacerbated.
As per the study conducted by Ward et al., (2019), recommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co‐administration of low‐dose methotrexate with TNFi is not recommended, nor is a strict treat‐to‐target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated.
Of the patients included in the study, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. Approximately half of the patients (45.1%) initiated etanercept, followed by adalimumab (28.6%), golimumab (11.7%), infliximab (11.7%), and certolizumab pegol (2.8%) as their index TNFi was stated in a study conducted by Walsh et al., (2018).
Continued in the report…..
Key Findings
At a dose of 160 mg, Efficacy response at week 96 in ASAS20 and ASAS40 was 76.9% and 64.6%, respectively, which is the highest as compared to all other therapies. Additionally, the Efficacy response at week 96 with shifting dose from 320mg to 160 mg in ASAS20 and ASAS40 was 79.8%, and 66.9%, respectively.
“A common treatment regimen for AS, involves medication, exercise, physical therapy, good posture practices, and other options such as applying heat/cold to help relax muscles and reduce joint pain. There are several different classes of biologics such as Cox Inhibitors, JAK inhibitors, TNF inhibitors, IL-17 inhibitors, IL-12 and IL-23, and much more available in the market for the treatment.
Drugs such as Humira, Enbrel, Remicade, Rayos, and Celebrex entered the market earlier between the years 2000–2010. While some of the drugs were recently approved by the FDA, these drugs include Taltz, Cosentyx, and Simponi Aria while Cimzia was approved in the year 2013. Drugs like, Humira (Adalimumab), Remicade (Infliximab), and Celebrex (Celecoxib) have lost their patent in the US, in 2016, 2018, and 2014 respectively, and their generics have enetered the market as well. Although the entry of generic drugs has historically spelled doom for the reference product, biosimilars are not likely to play the same role in the marketplace, at least at first. Due to these challenges, Remicade sales have not been substantially eroded by biosimilar competition just yet. Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis.
New therapies with selective biological drugs have emerged in the treatment of this pathology. Recently, the approval of Taltz (ixekizumab)—a new anti–IL-17A—for the treatment of ankylosing spondylitis, is anticipated to show positive growth in the market. The pipeline therapies belonging to IL-17A are estimated to generate a good market share due to their effectiveness and potential.”
The United States Market Outlook
This section provides the total AS market size and market size by therapies & class in the United States.
This section focuses on the rate of uptake of the potential drugs recently launched in the AS market or expected to get launched in the market during the study period 2018–2030. The analysis covers the AS market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for AS emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive and market Intelligence analysis of the AS market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Ankylosing Spondylitis (AS)
3. Disease Background and Overview: Ankylosing Spondylitis (AS)
3.1. Introduction
3.2. Severity based classification
3.2.1. Mild or early ankylosing spondylitis:
3.2.2. Severe or advanced AS:
3.3. Biology and pathology of AS
3.4. Etiology
3.4.1. Endogenous Factors
3.4.2. Exogenous Factors
3.5. Risk Factors of AS
3.5.1. Gender
3.5.2. Family History
3.5.3. Genetic Predisposition
3.5.4. Age
3.6. Signs and symptoms of AS
3.7. Genetics of ankylosing spondylitis — insights into pathogenesis
3.7.1. HLAB27 causing AS:
3.7.2. Antigen processing and presentation:
3.7.3. IL-17 and type 3 immunity in AS:
3.7.4. IL-17:
3.7.4.1. γδ T cells:
3.7.4.2. KIR3DL2+ T cells:
3.7.4.3. NKT cells:
3.7.4.4. Mast cells and neutrophils:
3.7.4.5. CD4 and CD8 T-cells:
3.7.5. IL-23 signaling:
3.7.6. Targeting type-3 immunity in AS:
3.8. Biomarkers
3.8.1. Genetic biomarkers
3.8.2. Markers for inflammation
3.8.3. Cartilage Turnover Markers
3.8.4. Other Biomarkers
3.9. Diagnosis
3.9.1. Examination
3.9.2. Genetics
3.9.3. Laboratory Findings
3.9.4. Imaging
3.9.5. Osteoporosis and Fracture
3.9.6. Observation
3.9.7. Mobility Testing
3.9.8. Strength Testing
3.9.9. Spine examination
3.10. Diagnostic Criteria
3.10.1. New York Classification Criteria: Diagnostic Criteria
4. Case Reports
4.1. Spinal subdural hematoma and ankylosing spondylitis: Case report and review of literature
4.2. Oral rehabilitation of a patient with ankylosing spondylitis and orofacial pain: A case report
5. Patient Journey
6. Epidemiology and Patient Population
6.1. KOL Views
6.2. Epidemiology Methodology
6.3. United States
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalence of Ankylosing Spondylitis in the United States
6.3.3. Diagnosed Prevalence of Ankylosing Spondylitis in the United States
6.3.4. Gender-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.5. Age-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.6. Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States
7. Current Treatment and Medical Practices
7.1. Therapy
7.2. Surgery
7.3. Lifestyle and home remedies
7.4. General Principles of Management
7.5. Treatment algorithm
7.6. Treatment Guidelines
7.6.1. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial Spondyloarthritis
8. Unmet needs
9. Marketed drugs
9.1. Key cross competition- Marketed drugs
9.2. Cimzia (Certolizumab pegol): UCB
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Developmental Activities
9.2.4. Clinical Development
9.2.4.1. Clinical Trials Information
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. Humira (adalimumab): AbbVie
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Other Developmental Activities
9.3.4. Clinical Development
9.3.4.1. Clinical Trials Information
9.3.5. Safety and Efficacy
9.3.6. Product Profile
9.4. Celebrex (celecoxib): Pfizer
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Other Developmental Activities
9.4.4. Clinical Development
9.4.4.1. Clinical Trials Information
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. Enbrel (Etanercept): Amgen/Pfizer
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Other Developmental Activities
9.5.4. Clinical Development
9.5.4.1. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Remicade (Infliximab): Janssen Biotech
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Other Developmental Activities
9.6.4. Clinical Development
9.6.4.1. Clinical Trials Information
9.6.5. Safety and Efficacy
9.6.6. Product Profile
9.7. Simponi (Golimumab): Janssen Biotech
9.7.1. Drug Description
9.7.2. Regulatory Milestones
9.7.3. Other Developmental Activities
9.7.4. Clinical Development
9.7.4.1. Clinical Trials Information
9.7.5. Safety and Efficacy
9.7.6. Product Profile
9.8. Vimovo (naproxen and esomeprazole magnesium): Pozen
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Other Developmental Activities
9.8.4. Clinical Development
9.8.4.1. Clinical Trials Information
9.8.5. Safety and Efficacy
9.8.6. Product Profile
9.9. Cosentyx: Novartis
9.9.1. Drug Description
9.9.2. Regulatory Milestones
9.9.3. Other Developmental Activities
9.9.4. Clinical Development
9.9.4.1. Clinical Trials Information
9.9.5. Safety and Efficacy
9.9.6. Product Profile
9.10. Indocin: Iroko Pharmaceuticals
9.10.1. Drug Description
9.10.2. Safety and Efficacy
9.10.3. Product Profile
9.11. Naprelan: Syntex Pharmaceuticals
9.11.1. Drug Description
9.11.2. Other Developmental Activities
9.11.3. Product Profile
9.12. Rayos (Prednisone): Horizon Pharma
9.12.1. Drug Description
9.12.2. Regulatory Milestones
9.12.3. Other Developmental Activities
9.12.4. Product Profile
9.13. Taltz (ixekizumab): Eli Lilly and Company
9.13.1. Drug Description
9.13.2. Regulatory Milestones
9.13.3. Other Development Activities
9.13.4. Clinical Development
9.13.4.1. Clinical Trials Information
9.13.5. Safety and Efficacy
9.13.6. Product Profile
10. Emerging Therapies
10.1. Key cross competition- Emerging Therapies
10.2. Tofacitinib: Pfizer
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.3.1. Clinical Trials Information
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Bimekizumab: UCB Biopharma
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.3.1. Clinical Trials Information
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.5. Ilumya (Tildrakizumab): Sun Pharma Global
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.3.1. Clinical Trials Information
10.5.4. Product Profile
10.6. Namilumab: Izana Bioscience
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.3.1. Clinical Trials Information
10.6.4. Product Profile
10.7. ILT-101(Interleukin 2): Iltoo Pharma
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.3.1. Clinical Trials Information
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Brodalumab (KHK4827): Kyowa Kirin
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.3.1. Clinical Trials Information
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.9. Rinvoq (Upadacitinib): Abbvie
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.3.1. Clinical Trials Information
10.9.4. Safety and Efficacy
10.9.5. Product Profile
11. Failed Therapies
11.1. Filgotinib: Galapagos/Gilead
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.3.1. Clinical Trials Information
11.1.4. Safety and Efficacy
11.1.5. Product Profile
12. Potential of Emerging Therapies and Current therapies
13. Attribute Analysis
14. Key Market Forecast Assumptions
15. Market Methodology
16. Ankylosing Spondylitis (AS): United States Market Outlook
16.1. United States Market Size
16.1.1. The total market size of Ankylosing Spondylitis
16.1.2. Market Size of Ankylosing Spondylitis by therapies
16.1.2.1. Market Size of Ankylosing Spondylitis by Class
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Reimbursement and Market access
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
List of Table
Table 1: Summary of Ankylosing Spondylitis (AS), Market, Epidemiology, and Key Events (2018–2030)
Table 2: Genetic Associations with AS
Table 3: Total Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 4: Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 5: Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 6: Age-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 7: Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Table 8: Principles of Management of AS
Table 9: Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial Spondyloarthritis
Table 10: Key cross competition- Marketed drugs
Table 11: Cimzia (certolizumab pegol), Clinical Trial Description, 2021
Table 12: Humira (adalimumab), Clinical Trial Description, 2021
Table 13: Celebrex (celecoxib), Clinical Trial Description, 2021
Table 14: Enbrel (Etanercept), Clinical Trial Description, 2021
Table 15: Remicade (Infliximab), Clinical Trial Description, 2021
Table 16: Simponi (Golimumab), Clinical Trial Description, 2021
Table 17: Vimovo (Esomeprazole/naproxen), Clinical Trial Description, 2021
Table 18: Cosentyx (secukinumab), Clinical Trial Description, 2021
Table 19: Taltz (ixekizumab), Clinical Trial Description, 2021
Table 20: Key cross competition- Emerging Therapies
Table 21: Tofacitinib, Clinical Trial Description, 2021
Table 22: Bimekizumab, Clinical Trial Description, 2021
Table 23: Filgotinib, Clinical Trial Description, 2021
Table 24: Tildrakizumab, Clinical Trial Description, 2021
Table 25: Namilumab, Clinical Trial Description, 2021
Table 26: ILT-101, Clinical Trial Description, 2021
Table 27: KHK4827, Clinical Trial Description, 2021
Table 28: Upadacitinib, Clinical Trial Description, 2021
Table 29: Key market forecast assumptions for Bimekizumab
Table 30: Key market forecast assumptions for Rinvoq
Table 31: Key market forecast assumptions for Brodalumab
Table 32: Key market forecast assumptions for Tofacitinib
Table 33: Key market forecast assumptions for Taltz
Table 34: United States Market Size of Ankylosing Spondylitis in USD Million (2018-2030)
Table 35: Market Size of Ankylosing Spondylitis by therapies in the US, in USD Million (2018-2030)
Table 36: Market Size of Ankylosing Spondylitis by Class in the US, in USD Million (2018-2030)
List of Figures
Figure 1: Possible Complications of Ankylosing Spondylitis
Figure 2: Pathology of entheses in AS
Figure 3: Risk Factors for Ankylosing Spondylitis
Figure 4: Functional roles of AS-associated genes
Figure 5: Antigen processing and presentation: potential link to AS
Figure 6: Multiple roles for HLA-B27 in the pathogenesis of Ankylosing spondylitis
Figure 7: Immune cells involved in the initiation, progression, and regulation of AS
Figure 8: The role of the gut in driving joint inflammation in ankylosing spondylitis
Figure 9: Potential mechanisms by which ERAP variants operate to influence disease risk in ankylosing spondylitis
Figure 10: ASAS classification criteria for axial and peripheral spondyloarthritis
Figure 11: Total Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 12: Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 13: Gender-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 14: Age-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 15: Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States (2018-2030)
Figure 16: Treatment Algorithm of AS
Figure 17: Summary of the main recommendations
Figure 18: Market Size of Ankylosing Spondylitis in the United States, in USD Millions (2018-2030)
Figure 19: Market Size of Ankylosing Spondylitis by therapies in the US, in USD Millions (2018-2030)
Figure 20: Market Size of Ankylosing Spondylitis by Class in the US, in USD Millions (2018-2030)
Figure 21: Market Barriers
Figure 22: SWOT Analysis of Ankylosing spondylitis
Pfizer
UCB Biopharma
